Trevi Therapeutics, Inc.
About Trevi Therapeutics, Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$42.8M
- Total assets
- $193.4M
- Market cap
- $1.9B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $51.5M
- Operating income
- -$51.5M
- Income tax
- -$30.0K
- Net income
- -$47.9M
- EPS (basic)
- $-0.47
- EPS (diluted)
- $-0.47
Balance sheet
- Total assets
- $110.9M
- Current assets
- $109.4M
- Total liabilities
- $11.3M
- Current liabilities
- $10.5M
- Shareholders’ equity
- $99.6M
Cash flow
- Operating cash flow
- -$38.3M
- Investing cash flow
- -$21.5M
- Financing cash flow
- $61.5M
- Net cash flow
- $1.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-0.47
- Shares outstanding
- 141.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 3, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $42.8M.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Trevi Therapeutics, Inc..
Write a review
News about Trevi Therapeutics, Inc.
News & sentiment via Polygon.io
